



CASE QA0259 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Laurelee A. Duncan
Type or print name

Laurelee A. Duncan
Signature

11/01/05
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ASHOK V. PURANDARE

APPLICATION NO: 10/648,677

FILED: AUGUST 25, 2003

FOR: ANTAGONISTS OF CHEMOKINE RECEPTORS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-5323


Laurelee A. Duncan
Attorney for Applicant
Reg. No. 44,096

Date: 11/1/05

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)


 ATTY. DOCKET NO.
QA0259 NP
APPLICATION NO.
10/648,677
APPLICANT
Ashok V. Purandare
FILING DATE
AUGUST 25, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,245,332	6/12/01	Butcher et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Campbell, J. J., et al., J. Immunol. 163: pp. 2353 - 2357 (1999)
	AS	Campbell, J. J., et al., Nature, 400: pp. 776 - 780 (1999)
	AT	Sallusto, F., et al., Eur. J. Immunol. 29: pp. 1617 - 1625 (1999)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
QA0259 NP
APPLICATION NO.
10/648,677
APPLICANT
Ashok V. Purandare
FILING DATE
AUGUST 25, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Tang, H. L. et al., Science 284: pp. 819 - 822 (1999)
AB	Krueger, J. G., J. Am. Acad. Dermatol 46: pp. 1 - 23 (2002)
AC	Wakugawa M. et al., Drug News and Perspective 15(3): pp. 175 - 179 (2002)
AD	Vestergaard et al., J. Clin. Invest. 104(8): pp 1097 - 1105 (1999)
AE	Vestergaard et al., J. Investigative Dermatology, 115: pp. 640 - 646 (2000)
AF	Okazaki et al., Clin. Exp. Allergy; 32: pp. 1236 - 1242, 2002
AG	Lloyd et al., J. Exp. Med. 191 (2): pp. 265 - 273 (2000)
AH	Ramos et al., Immunol. Rev. 177: pp. 31 - 42 (2000)
AI	Lukacs et al., J. of Immunology 171(1): pp. 11 - 15 (2003)
AJ	Lloyd et al., Current Opin. In pharmacol 3: pp. 443 - 448 (2003)
AK	Randolph, et al., J. Immunol. 162: pp. 2375 - 2383 (1999)
AL	Jakubzick et al., Am. J. of Pathology, 165(4): pp. 1211- 1221 (2204)
AM	Gonzalo et al., J. Immunol., 163(1): pp. 403 - 411 (1999)
AN	Schuh et al., FASEB J., 16(10): pp. 1313 - 1315 (2002)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
QA0259 NP
APPLICATION NO.
10/648,677
APPLICANT
Ashok V. Purandare
FILING DATE
AUGUST 25, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AA	Belperio et al., J. Immunol, 173(7): pp. 4692 – 4698 (2004)
	AB	Bordignon et al., J. Clin. Invest. 107(11): pp. 1357 – 1364 (2001)
	AC	Ruth et al., Arthritis Rheum, 44(5): pp. 2750 – 2760 (2001)
	AD	Thompson et al., J. Immunol. 166: pp. 6899 – 6906 (2001)
	AE	Biedermann et al., Eur. J. Immunol. 32(11): pp. 3171 – 3180 (2202)
	AF	Katschke et al., Arthritis and Rheum, 44(5): pp. 1022 – 1032 (2001)
	AG	Kawasaki et al., J. Immunology 166(3) pp. 2055 – 2062 (2001)
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.